<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03574688</url>
  </required_header>
  <id_info>
    <org_study_id>2016894_PILOT</org_study_id>
    <nct_id>NCT03574688</nct_id>
  </id_info>
  <brief_title>The Hydration to Optimize Metabolism (H2O Metabolism) Pilot Study</brief_title>
  <acronym>H2OMetaboPilot</acronym>
  <official_title>The Hydration to Optimize Metabolism (H2O Metabolism) Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Region Skane</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Lund University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Danone Research</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Region Skane</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates increased hydration (1.5 L of water daily during 6 weeks) on top of
      habitual water intake in the lowering of the vasopressin marker copeptin and in the lowering
      of plasma glucose concentration in adults with signs of low water intake at recruitment
      (elevated levels of copeptin, high urine osmolality, low urine volume).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      High plasma concentration of vasopressin (i.e. antidiuretic hormone) is a novel and
      independent risk factor for type 2 diabetes, the metabolic syndrome, cardiovascular disease
      and premature death. The main physiological role of vasopressin is to maintain constant
      plasma osmolality. Previous studies in rats and a Mendelian randomization study in humans
      suggest causality between elevated vasopressin concentration and elevated plasma glucose
      concentration. As vasopressin can be suppressed by increasing water intake, the investigators
      hypothesize that water supplementation in individuals with high vasopressin can lower plasma
      glucose and prevent diabetes.

      The aim of this pilot study is to test if six weeks of water supplementation of 1.5 Liters of
      extra water per day in low-drinkers with high copeptin can significantly alter hydration
      markers in general and reduce plasma copeptin in particular. Furthermore, the investigators
      also aim at investigating whether this 6-week water intervention can significantly reduce
      fasting plasma glucose concentration.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 2, 2017</start_date>
  <completion_date type="Actual">July 25, 2017</completion_date>
  <primary_completion_date type="Actual">July 25, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>All participants of this pilot intervention study had the intervention of 1.5 Liters of increased daily water intake per day during 6 weeks.</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Fasting plasma copeptin concentration (pmol/L)</measure>
    <time_frame>6 weeks</time_frame>
    <description>Change of fasting plasma copeptin between baseline and after 6 weeks of increased water intake.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>24 hour urine osmolality (mosm/kg H2O)</measure>
    <time_frame>6 weeks</time_frame>
    <description>Change of 24 hour urine osmolality between baseline and after 6 weeks of increased water intake.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>24 hour urine volume (L/24h)</measure>
    <time_frame>6 weeks</time_frame>
    <description>Change of 24 hour urine volume between baseline and after 6 weeks of increased water intake.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Drinking water (L/day)</measure>
    <time_frame>6 weeks</time_frame>
    <description>Change of intake of tap and bottled water between baseline and after 6 weeks of increased water intake.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total water (L/day)</measure>
    <time_frame>6 weeks</time_frame>
    <description>Change of total water intake between baseline and after 6 weeks of increased water intake.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting plasma glucose concentration (mmol/L)</measure>
    <time_frame>6 weeks</time_frame>
    <description>Change of Fasting plasma glucose concentration between baseline and after 6 weeks of increased water intake.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">34</enrollment>
  <condition>Low Water Intake</condition>
  <condition>High Vasopressin</condition>
  <arm_group>
    <arm_group_label>Water intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The participants increase their habitual daily water intake with 1.5 Liters of tap water per day during 6 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Water</intervention_name>
    <description>Increased daily water intake with 1.5 Liters of water per day on top of habitual water intake.</description>
    <arm_group_label>Water intervention</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Provision of informed consent

          -  Age 20-75 years

          -  High plasma concentration of copeptin of &gt;6.1 pmol/L in women and &gt; 10.7 pmol/L in men

          -  24-hour urine osmolality &gt; 600 milliosmol (mosm) /kg water.

        Exclusion Criteria:

          -  24-hour urine volume &gt;1.5 L

          -  Pregnancy or breastfeeding

          -  Plasma sodium &lt;135 mmol/L

          -  Use of diuretics, lithium or SSRI drugs

          -  Chronic kidney disease (estimated glomerular filtration rate &lt; 30mL/min)

          -  Heart failure

          -  Inflammatory bowel disease

          -  Type 1 diabetes or type 2 diabetes treated with insulin

          -  Vulnerable subjects (subjects with legal guardian, with loss of personal liberty)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Olle Melander, M.D., Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>Lund University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>KFE, Skåne University Hospital in Malmö</name>
      <address>
        <city>Malmö</city>
        <zip>20502</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>June 2018</verification_date>
  <study_first_submitted>June 20, 2018</study_first_submitted>
  <study_first_submitted_qc>June 20, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 2, 2018</study_first_posted>
  <last_update_submitted>June 30, 2018</last_update_submitted>
  <last_update_submitted_qc>June 30, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">July 3, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Region Skane</investigator_affiliation>
    <investigator_full_name>Olle Melander</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Hydration</keyword>
  <keyword>Water</keyword>
  <keyword>Vasopressin</keyword>
  <keyword>Copeptin</keyword>
  <keyword>Glucose</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>June 18, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/88/NCT03574688/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

